{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"58","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Patient response to the treatment were determined by the definitions for complete response, partial response, marginal response, stable disease, and progressive disease outlined by IMBTR/ABMTR (Blade criteria). Progression free survival was summarized using point estimates of the median time to progression and associated 95% confidence intervals. The data was presented graphically using Kaplan-Meier plots. Exploratory analysis, including multivariate Cox regression with demographic variables and markers of myeloma activity as covariates was performed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally","id":"OG000","title":"Bevacizumab, Dexamethasone, and Lenalidomide"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to five years","title":"Progression Free Survival (Time to Progression)","type":"PRIMARY","unitOfMeasure":"months"}